Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin–Angiotensin–Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective

INTRODUCTION: Hyperkalemia is associated with increased morbidity and mortality in patients with chronic kidney disease (CKD). Patiromer (Veltassa(®)) is an oral potassium binder indicated for the treatment of hyperkalemia in adults. We evaluated the impact of patiromer on the Swiss healthcare resou...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Barbara, Serra, Andreas, Telser, Harry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122858/
https://www.ncbi.nlm.nih.gov/pubmed/35416597
http://dx.doi.org/10.1007/s12325-022-02123-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122858/
https://www.ncbi.nlm.nih.gov/pubmed/35416597
http://dx.doi.org/10.1007/s12325-022-02123-3

Ejemplares similares